▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #270 by analyst upside · 2026-09-27
CATX
Perspective Therapeutics, Inc.
Healthcare · Market Cap $288M · P/E 0x
ANALYST PRICE TARGET
+387.5%
implied upside to consensus target
Current Price $2.52
Consensus Target $12.29
Bull Target $18.0
Bear Target $5.0
Analysts Covering 14
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
11
Hold
1
Sell
0
52-Week Low $1.96
52-Week High $6.16
YTD Return -9.7%
FUNDAMENTALS
Market Cap $288M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.33
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.96
52-Week High $6.16
Current Price $2.52
Bear Target $5.0
Bull Target $18.0
● Now $2.52 ● Target $12.29
TRADING DATA
Avg Volume 1.6M
YTD Return -9.7%
Analyst Count 14
Consensus Buy
Upside to Target +387.5%
Last Updated 2026-09-27

ANALYST SUMMARY

Perspective Therapeutics, Inc. (CATX) is currently trading at $2.52 with a Wall Street consensus price target of $12.29, implying potential upside of 387.5% over the next 12 months. 14 analysts currently cover CATX, with a consensus rating of Buy - 93% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $18.0, while the most cautious has a target of $5.0.

CATX operates in the Healthcare sector with a market capitalisation of $288M. The stock is down 9.7% year-to-date and is currently trading near the lower end of its 52-week range of $1.96 – $6.16.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

QTTB +381.8%
Q32 Bio Inc.
$261M · P/E 2.8x · Buy
PLX +304.4%
Protalix BioTherapeutics, Inc.
$219M · P/E 11.8x · Buy
XFOR +285.4%
X4 Pharmaceuticals, Inc.
$298M · P/E 2.2x · Buy
SABS +253.7%
SAB Biotherapeutics, Inc.
$299M · P/E 13.7x · Buy
AGEN +208.4%
Agenus Inc.
$386M · P/E 2.8x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CATX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

William Blair ● Initiated
Outperform 2026-09-18 44% win rate (9 calls)
Wedbush reit
Outperform → Outperform 2026-09-15 Building track record
BMO Capital ● Initiated
Outperform 2026-08-19 Building track record
B of A Securities - Reiterated
Neutral → Neutral 2026-08-14 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2026-08-11 14% win rate (7 calls)
Wedbush reit
Outperform → Outperform 2026-05-05 Building track record
Wedbush reit
Outperform → Outperform 2026-04-20 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-03-23 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
43
out of 100
Coverage depth
21/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →